$GEVO

Agiri Oluwagbemileke Yusuf sold $57K of GEVO

Agiri Oluwagbemileke Yusuf (CFO) sold 31,958 shares of Gevo, Inc. (GEVO) at $1.77 on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Agiri Oluwagbemileke Yusuf
Published May 29, 2026, 9:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GEVO
Neutral
medium confidence
Mentioned
$GEVO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GEVONeutralLow
01

Why it matters

This is a disclosure of an executed sale, not a new company event. The main tradable element is potential short-term sentiment/technical positioning around the filing date.

02

Market read

Traders may monitor GEVO for any follow-through in selling pressure, but the 10b5-1 framing suggests limited informational content.

03

What to watch

The article provides only the sale size/price; it does not indicate whether other insiders/funds are buying, nor any concurrent company-specific news.

Relevance 6/10Novelty 3/10Timing: Disclosure filed May 29; sale executed May 27.

Background

SEC Form 4 reports an officer’s transaction in the issuer’s shares; 10b5-1 indicates the trade was planned in advance.

Company-level read

Ticker impact

$GEVONeutralMedium confidence
Context

Gevo CFO Agiri Oluwagbemileke Yusuf sold 31,958 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Limited, mostly sentiment/positioning impact; watch for follow-on selling or unusual volume around the disclosure window.

Evidence & confidence

The filing is a routine insider transaction and explicitly tied to a pre-arranged 10b5-1 plan, reducing the likelihood of new negative information.

Market effects

Minimal—single-company insider sale without new operational/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal risk management or valuation concerns, so traders may still fade strength.

Key entities

  • Gevo, Inc.

    Subject of the insider transaction disclosure (CFO sale under 10b5-1).

  • Agiri Oluwagbemileke Yusuf

    CFO who sold 31,958 shares at $1.7727/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GEVOMedAI 8/10

Gevo (GEVO) Q2 2026 Earnings Call Transcript

Gevo (GEVO) reported Q2 2026 revenue of $47 million, up 7% year over year, and non-GAAP adjusted EBITDA of $11 million. Full-year 2026 adjusted EBITDA guidance is now above $60 million. The company targets $70 million of 45Z tax credit monetization in 2026 and recorded a $176 million noncash impairment tied to exiting its ATJ-60 project.

$GEVOHigh

Gevo, Inc. (GEVO): Results of Operations and Financial Condition

Gevo, Inc. (GEVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Gevo Reports Second Quarter Results and Raises Financial Expectations for Full-Year 2026 ENGLEWOOD, Colo. – August 6, 2026 – Gevo, Inc. (NASDAQ: GEVO), a leader in renewable fuels, chemicals and carbon management, today announced its financial results for the second

$GEVOMedAI 8/10

Why Is Gevo (GEVO) Stock Rocketing Higher Today

Gevo (NASDAQ: GEVO) shares rose about 7.5% after the company said it expects 2026 non-GAAP Adjusted EBITDA to be more than double prior estimates. Gevo attributed the upgrade to new carbon pathways, higher production, and cost reductions, and it announced Todd Werpy, Ph.D., joining its board. The stock is volatile and trades at $1.68.